



**GMP-ZERTIFIKAT / CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER**

Zertifikat Nr.: / *Certificate No.:* INS-481892-0003-001

**Teil 1 / Part 1**

Ausgestellt auf Basis einer Inspektion in Übereinstimmung mit /  
*Issued following an inspection in accordance with*

**Art. 111(5) of Directive 2001/83/EC**

**Art. 80(5) of Directive 2001/82/EC**

**Art. 15 of Directive 2001/20/EC**

Die zuständige Behörde **Österreichs** bestätigt wie folgt: /  
*The competent authority of **Austria** confirms the following.*

Der Betrieb / *The manufacturer*

**Indiana Blood Center, Inc.**  
**3450 N. Meridian Street**  
**46208 IN Indianapolis**

wurde inspiziert auf Grundlage einer Auflistung in den Zulassungsunterlagen als Hersteller mit Sitz  
außerhalb des Europäischen Wirtschaftsraumes, auf Basis von /  
*has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of  
the European Economic Area in accordance with*

**Art. 8(2)/33(2)/19(3)/44(3)\* of Regulation (EC) 726/2004\***

**Art. 111(4) of Directive 2001/83/EC**

**Art. 80(4) of Directive 2001/82/EC**

umgesetzt in folgende nationale Gesetzgebung / *transposed in the following national legislation:*  
,Verordnung der Bundesministerin für Gesundheit und Frauen betreffend Betriebe, die Arzneimittel  
herstellen, kontrollieren oder in Verkehr bringen (Arzneimittelbetriebsordnung 2009 - AMBO 2009),  
BGBl. II Nr. 324/2008'.

Aus der während der Inspektion des betreffenden Herstellers gewonnenen Kenntnis, zuletzt durchgeführt  
am /

*From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on*

**19.09.2017** , für/for 3,5 Tag(e) / *day(s)*

kann angenommen werden, dass /  
*it is considered that it complies with*

den Richtlinien der Guten Herstellungspraxis<sup>1</sup> entsprochen wird, festgehalten in /  
*The principles and guidelines of Good Manufacturing Practice<sup>1</sup> laid down in*



**GMP-ZERTIFIKAT / CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER**

Zertifikat Nr.: / Certificate No.: INS-481892-0003-001

- 40  **Directive 2003/94/EC**  
41  **Directive 91/412/EEC**  
42  **der Richtlinie der GMP für Wirkstoffe (Art. 47 of Directive 2001/83/EC und Art. 51 of**  
43 **Directive 2001/82/EC) / The principles of GMP for active substances (Art. 47 of**  
44 **Directive 2001/83/EC and Art. 51 of Directive 2001/82/EC).**

45 Dieses Zertifikat spiegelt den Status der Betriebsstätte zum Zeitpunkt der oben genannten Inspektion. Es  
46 sollte nicht zur Bestätigung der Übereinstimmung herangezogen werden, wenn seit der genannten  
47 Inspektion mehr als drei Jahre vergangen sind. Die Gültigkeitsdauer kann unter Verwendung eines  
48 regulatorischen Risikomanagements durch einen Eintrag in das Feld Einschränkungen oder Erklärungen  
49 verkürzt oder verlängert werden.

50 *This certificate reflects the status of the manufacturing site at the time of the inspection noted above and*  
51 *should not be relied upon to reflect the compliance status if more than three years have elapsed since*  
52 *the date of that inspection. However, this period of validity may be reduced or extended using regulatory*  
53 *risk management principles by an entry in the Restrictions or Clarifying remarks field*

54 Das Zertifikat ist nur bei Vorlage sämtlicher Seiten und beider Teile (1 und 2) gültig.  
55 *This certificate is valid only when presented with all pages and both Parts 1 and 2.*

56  
57 <sup>1</sup> *These requirements fulfil the GMP recommendations of WHO.*  
58 (\*) *Nichtzutreffendes streichen / delete that which does not apply*  
59



**GMP-ZERTIFIKAT / CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER**

Zertifikat Nr.: / Certificate No.: INS-481892-0003-001

**Teil 2 / Part 2**

Humanarzneimittel / *Human Medicinal Products*

Veterinärarzneimittel / *Veterinary Medicinal Products*

Prüfpräparate zur klinischen Prüfung / *Human Investigational Medicinal Products*

Phase I    Phase II    Phase III    Phase IV

**Teil 1 – HERSTELLUNGSTÄTIGKEITEN / Part 1 – MANUFACTURING OPERATIONS**

**1.4 Andere Produkte oder Herstellungstätigkeiten / Other products or manufacturing activity**

(jede andere relevante Herstellungsaktivität/ Produktart, die oben nicht erwähnt ist, z.B. Sterilisation von Wirkstoffen, Herstellung von biologischen Ausgangsstoffen (sofern durch nationale Vorschriften vorgesehen), pflanzliche oder homöopathische Produkte, Bulk oder vollständige Herstellung usw.)  
(any other relevant manufacturing activity/product type that is not covered above e.g. sterilisation of active substances, manufacture of biological active starting materials (when required by national legislation), herbal or homeopathic products, bulk or total manufacturing, etc).

**1.4.1 Herstellung von: / Manufacture of:**

1.4.1.3 Anderen: / *Others:*

Humanplasma zur Fraktionierung / *Human Plasma for Fractionation*

**1.6 Qualitätskontrolle / Quality control testing**

**1.6.3 Chemisch/Physikalisch / Chemical/Physical**

**1.6.4 Biologisch / Biological**

Mögliche Einschränkungen oder Erklärungen bezüglich des vorliegenden Zertifikats /  
*Any restrictions or clarifying remarks related to the scope of this certificate:*

**Keine / none**

Für das Bundesamt für Sicherheit im Gesundheitswesen /  
*For the Federal Office for Safety in Health Care*





Octapharma Pharmazeutika Produktions GmbH  
Denisia Wurstbauer  
Oberlaaer Straße 235  
A-1100 Vienna

**Date:** 08 October 2019  
**Contact:** Karmin Saadat  
**T:** +43 (0)505 55-36213  
**E-Mail:** inspektionen@ages.at  
**Reference:** INS-481892-0004-004

**INSPECTION OF THIRD COUNTRY SOURCE PLASMA / RECOVERED PLASMA SITES FOR  
Octapharma Pharmazeutika Produktions GmbH**

Dear Mrs. Wurstbauer,

We refer to the inspection performed for your company at Indiana Blood Center, Inc., 3450 N Meridian Street, 46208 Indianapolis, IN on 19 – 22 September 2017 by the Austrian Agency for Health and Food Safety (AGES).

On the basis of the inspection performed on 19 – 22 September 2017, and subsequent correspondence, we can confirm that your operations relating to the safety and quality of plasma are in general compliance with the requirements of Commission Directives 2004/33/EC and 2005/62/EC implementing Directive 2002/98/EC of the European Parliament and of the Council, the relevant European Pharmacopoeia Monograph(s) and Directive 2003/94/EC.

This letter reflects the status of the plasma collection site at the time of the inspection noted above. The Issuing Authority has established appropriate inspection and control measures for the above named site to deem it compliant until September 2021. This letter should not be relied upon to reflect the compliance status if the above mentioned date has been exceeded, after which the issuing authority should be consulted.

The listing of this site in EMEA/H/PMF/000008/05 will be recommended.


Any matters arising from this inspection will be reviewed at the next inspection.

On behalf of the Austrian Federal Office for Safety in Health Care

*See official electronic signature at the end of the document*



Saadat Karmin  
am 8.10.2019

	<p>Dieses Dokument wurde amtssigniert. Informationen zur Prüfung der elektronischen Signatur und des Ausdrucks finden Sie unter <a href="http://www.basg.gv.at/amtssignatur">http://www.basg.gv.at/amtssignatur</a>.</p> <p>Bundesamt für Sicherheit im Gesundheitswesen Traisengasse 5, 1200 Wien</p>	
	<p>Signaturwert</p>	<p>mvaWuWalfw/omTuPvpgiifpkzPhwd ub/lhDWDmPSDaWz1ofGPo/DvdhrB5 obcsW5nfGmT2udSPktfnoleDnWB Tohvvz0atewD5AgolrBuTsroi 0//T/tDTrcru5oGrobGPT5frle/ IGASunwgnAaincSSpcDnpGu2etv WfWuWnkgmPpSIBAApuslp2vc1/Bt2bkwaf0AP2lw</p>



Octapharma Pharmazeutika Produktions GmbH  
Denisia Wurstbauer  
Oberlaaer Straße 235  
A-1100 Vienna

**Date:** 08 October 2019  
**Contact:** Karmin Saadat  
**T:** +43 (0)505 55-36213  
**E-Mail:** inspektionen@ages.at  
**Reference:** INS-482941-0001-004

**INSPECTION OF THIRD COUNTRY SOURCE PLASMA / RECOVERED PLASMA SITES FOR  
Octapharma Pharmazeutika Produktions GmbH**

Dear Mrs. Wurstbauer,

We refer to the inspection performed for your company at Indiana Blood Center – Laboratory 3450 N Meridian Street, 46208 Indianapolis, IN on 19 – 22 September 2017 by the Austrian Agency for Health and Food Safety (AGES).

On the basis of the inspection performed on 19 – 22 September 2017, and subsequent correspondence, we can confirm that your operations relating to the safety and quality of plasma are in general compliance with the requirements of Commission Directives 2004/33/EC and 2005/62/EC implementing Directive 2002/98/EC of the European Parliament and of the Council, the relevant European Pharmacopoeia Monograph(s) and Directive 2003/94/EC.

This letter reflects the status of the plasma collection site at the time of the inspection noted above. The Issuing Authority has established appropriate inspection and control measures for the above named site to deem it compliant until September 2021. This letter should not be relied upon to reflect the compliance status if the above mentioned date has been exceeded, after which the issuing authority should be consulted.

The listing of this site in EMEA/H/PMF/000008/05 will be recommended.


Any matters arising from this inspection will be reviewed at the next inspection.

On behalf of the Austrian Federal Office for Safety in Health Care

*See official electronic signature at the end of the document*



Saadat Karmin  
am 8.10.2019

	<p>Dieses Dokument wurde amtssigniert. Informationen zur Prüfung der elektronischen Signatur und des Ausdrucks finden Sie unter <a href="http://www.basg.gv.at/amtssignatur">http://www.basg.gv.at/amtssignatur</a>.</p> <p>Bundesamt für Sicherheit im Gesundheitswesen Traisengasse 5, 1200 Wien</p>	
	<p>Signaturwert</p>	<p>cnDb2Guwhpc2d/cs0giAl/aPuvgs/2T DnwmWkgeozobuialzArw1ApdDsi m/w/lo0hgkgnTDSznBu1IsPADSWs /dWBmdTWcbl0kecGtS/BPwpDDfv/BBwGiB rPnorhGcbogTkk1mn/zokpfuo Bm2c0S2iaGsmGdzigSdAIDbl fhrPI0sbfb2zsvbmbPcB5lcrPSB</p>



Octapharma Pharmazeutika Produktions GmbH  
Denisia Wurstbauer  
Oberlaaer Straße 235  
A-1100 Vienna

**Date:** 08 October 2019  
**Contact:** Karmin Saadat  
**T:** +43 (0)505 55-36213  
**E-Mail:** inspektionen@ages.at  
**Reference:** INS-482943-0001-004

**INSPECTION OF THIRD COUNTRY SOURCE PLASMA / RECOVERED PLASMA SITES FOR  
Octapharma Pharmazeutika Produktions GmbH**

Dear Mrs. Wurstbauer,

We refer to the inspection performed for your company at Indiana Blood Center – 2726 Adams Street Suite 150, 46032 Carmel IN on 19 – 22 September 2017 by the Austrian Agency for Health and Food Safety (AGES).

On the basis of the inspection performed on 19 – 22 September 2017, and subsequent correspondence, we can confirm that your operations relating to the safety and quality of plasma are in general compliance with the requirements of Commission Directives 2004/33/EC and 2005/62/EC implementing Directive 2002/98/EC of the European Parliament and of the Council, the relevant European Pharmacopoeia Monograph(s) and Directive 2003/94/EC.

This letter reflects the status of the plasma collection site at the time of the inspection noted above. The Issuing Authority has established appropriate inspection and control measures for the above named site to deem it compliant until September 2021. This letter should not be relied upon to reflect the compliance status if the above mentioned date has been exceeded, after which the issuing authority should be consulted.

The listing of this site in EMEA/H/PMF/000008/05 will be recommended.

Any matters arising from this inspection will be reviewed at the next inspection.

On behalf of the Austrian Federal Office for Safety in Health Care

*See official electronic signature at the end of the document*





Saadat Karmin  
am 8.10.2019

	<p>Dieses Dokument wurde amtssigniert. Informationen zur Prüfung der elektronischen Signatur und des Ausdrucks finden Sie unter <a href="http://www.basg.gv.at/amtssignatur">http://www.basg.gv.at/amtssignatur</a>.</p> <p>Bundesamt für Sicherheit im Gesundheitswesen Traisengasse 5, 1200 Wien</p>	
	Signaturwert	<p>1TaScrlresvdo1shwd/kTDwdul/t0l Tlo2bdAs0gftTTtw/Pt5wBahvSezltmf ti0AbcDdr2InWtgp2ke0gvac mezSvvcPSoasnB2WSePvmDocpP5iB Gevzknc00bmvWznp5mlzuoom5s W1r2vkcVpVwnBzpbP1elp0ozTz mzpbdgBIBcfImunPwluahrbdIirzw</p>



Octapharma Pharmazeutika Produktions GmbH  
Denisia Wurstbauer  
Oberlaaer Straße 235  
A-1100 Vienna

**Date:** 08 October 2019  
**Contact:** Karmin Saadat  
**T:** +43 (0)505 55-36213  
**E-Mail:** inspektionen@ages.at  
**Reference:** INS-482945-0001-004

**INSPECTION OF THIRD COUNTRY SOURCE PLASMA / RECOVERED PLASMA SITES FOR  
Octapharma Pharmazeutika Produktions GmbH**

Dear Mrs. Wurstbauer,

We refer to the inspection performed for your company at Indiana Blood Center – 11005 Allisonville Road, 46038, Fishers IN on 19 – 22 September 2017 by the Austrian Agency for Health and Food Safety (AGES).

On the basis of the inspection performed on 19 – 22 September 2017, and subsequent correspondence, we can confirm that your operations relating to the safety and quality of plasma are in general compliance with the requirements of Commission Directives 2004/33/EC and 2005/62/EC implementing Directive 2002/98/EC of the European Parliament and of the Council, the relevant European Pharmacopoeia Monograph(s) and Directive 2003/94/EC.

This letter reflects the status of the plasma collection site at the time of the inspection noted above. The Issuing Authority has established appropriate inspection and control measures for the above named site to deem it compliant until September 2021. This letter should not be relied upon to reflect the compliance status if the above mentioned date has been exceeded, after which the issuing authority should be consulted.

The listing of this site in EMEA/H/PMF/000008/05 will be recommended.


Any matters arising from this inspection will be reviewed at the next inspection.

On behalf of the Austrian Federal Office for Safety in Health Care

*See official electronic signature at the end of the document*



Saadat Karmin  
am 8.10.2019

	<p>Dieses Dokument wurde amtssigniert. Informationen zur Prüfung der elektronischen Signatur und des Ausdrucks finden Sie unter <a href="http://www.basg.gv.at/amtssignatur">http://www.basg.gv.at/amtssignatur</a>.</p> <p>Bundesamt für Sicherheit im Gesundheitswesen Traisengasse 5, 1200 Wien</p>	
	<p>Signaturwert</p>	<p>rBS2armnPIWvo2rrTrnAiiwgdefTaw Bwfupklbhft1ogrBvib5d Srgit/mTmvSaP2WDATrBhA/SwSoGkS5 vmpT2iD10zGznkDtamhka/Ggl bGpwlebuVPvi2olG/lzbms1fuz2u /acatsovSbckSlGrl2u/PprPPgSlp agzk5ltmhrdt/de5DD10ko2SoaPS</p>



Octapharma Pharmazeutika Produktions GmbH  
Denisia Wurstbauer  
Oberlaaer Straße 235  
A-1100 Vienna

**Date:** 08 October 2019  
**Contact:** Karmin Saadat  
**T:** +43 (0)505 55-36213  
**E-Mail:** inspektionen@ages.at  
**Reference:** INS-482942-0001-004

**INSPECTION OF THIRD COUNTRY SOURCE PLASMA / RECOVERED PLASMA SITES FOR  
Octapharma Pharmazeutika Produktions GmbH**

Dear Mrs. Wurstbauer,

We refer to the inspection performed for your company at Indiana Blood Center – Market Square 2200 Elmwood Avenue Suite D 16, 47904 Lafayette, IN on 19 – 22 September 2017 by the Austrian Agency for Health and Food Safety (AGES).

On the basis of the inspection performed on 19 – 22 September 2017, and subsequent correspondence, we can confirm that your operations relating to the safety and quality of plasma are in general compliance with the requirements of Commission Directives 2004/33/EC and 2005/62/EC implementing Directive 2002/98/EC of the European Parliament and of the Council, the relevant European Pharmacopoeia Monograph(s) and Directive 2003/94/EC.

This letter reflects the status of the plasma collection site at the time of the inspection noted above. The Issuing Authority has established appropriate inspection and control measures for the above named site to deem it compliant until September 2021. This letter should not be relied upon to reflect the compliance status if the above mentioned date has been exceeded, after which the issuing authority should be consulted.

The listing of this site in EMEA/H/PMF/000008/05 will be recommended.


Any matters arising from this inspection will be reviewed at the next inspection.

On behalf of the Austrian Federal Office for Safety in Health Care

*See official electronic signature at the end of the document*



Saadat Karmin  
am 8.10.2019

	<p>Dieses Dokument wurde amtssigniert. Informationen zur Prüfung der elektronischen Signatur und des Ausdrucks finden Sie unter <a href="http://www.basg.gv.at/amtssignatur">http://www.basg.gv.at/amtssignatur</a>.</p> <p>Bundesamt für Sicherheit im Gesundheitswesen Traisengasse 5, 1200 Wien</p>	
	Signaturwert	<p>2hlu1vP5aA2/nzcbc01veWl5ugb0go hiPodwriTv/5gcp/pccml/5A5tp5TK hlu22w020iwehIkBz1fkGbl1riDinnG 25rITPDr1oiSWabSnPzDrBlmfhPDdG fbrlhwpvgus2frfeccnDIPir0 ovoDzBm0aubneDpBhlnAh5ibdAPb 2PodarWguvASuz0tImpAagllDkvmg</p>



Octapharma Pharmazeutika Produktions GmbH  
Denisia Wurstbauer  
Oberlaaer Straße 235  
A-1100 Vienna

**Date:** 08 October 2019  
**Contact:** Karmin Saadat  
**T:** +43 (0)505 55-36213  
**E-Mail:** inspektionen@ages.at  
**Reference:** INS-482946-0001-004

**INSPECTION OF THIRD COUNTRY SOURCE PLASMA / RECOVERED PLASMA SITES FOR  
Octapharma Pharmazeutika Produktions GmbH**

Dear Mrs. Wurstbauer,

We refer to the inspection performed for your company at Indiana Blood Center – 8739 US Highway 31, South Indianapolis, 46227 IN on 19 – 22 September 2017 by the Austrian Agency for Health and Food Safety (AGES).

On the basis of the inspection performed on 19 – 22 September 2017, and subsequent correspondence, we can confirm that your operations relating to the safety and quality of plasma are in general compliance with the requirements of Commission Directives 2004/33/EC and 2005/62/EC implementing Directive 2002/98/EC of the European Parliament and of the Council, the relevant European Pharmacopoeia Monograph(s) and Directive 2003/94/EC.

This letter reflects the status of the plasma collection site at the time of the inspection noted above. The Issuing Authority has established appropriate inspection and control measures for the above named site to deem it compliant until September 2021. This letter should not be relied upon to reflect the compliance status if the above mentioned date has been exceeded, after which the issuing authority should be consulted.

The listing of this site in EMEA/H/PMF/000008/05 will be recommended.

Any matters arising from this inspection will be reviewed at the next inspection.

On behalf of the Austrian Federal Office for Safety in Health Care

*See official electronic signature at the end of the document*



Saadat Karmin  
am 8.10.2019

	<p>Dieses Dokument wurde amtssigniert. Informationen zur Prüfung der elektronischen Signatur und des Ausdrucks finden Sie unter <a href="http://www.basg.gv.at/amtssignatur">http://www.basg.gv.at/amtssignatur</a>.</p> <p>Bundesamt für Sicherheit im Gesundheitswesen Traisengasse 5, 1200 Wien</p>	
	Signaturwert	<p>puAphA0BgAbhgnuTb1hmoc/gzStmw1 /DIAdlhczTa21vPe5iAbSmPvWckfg nw20odTDsDk1gD5vfvAhTvIAb Snlwcnfclb/gukS0pgolGovBIG slekkaASiiGuuDsm0TrreWceDuwz uv/zvWeeBgSvd5cmni1ows12TcsmBGn/ eW1sifsWvSomfilS10gWlgA</p>



Octapharma Pharmazeutika Produktions GmbH  
Denisia Wurstbauer  
Oberlaaer Straße 235  
A-1100 Vienna

**Date:** 08 October 2019  
**Contact:** Karmin Saadat  
**T:** +43 (0)505 55-36213  
**E-Mail:** inspektionen@ages.at  
**Reference:** INS-482944-0001-004

**INSPECTION OF THIRD COUNTRY SOURCE PLASMA / RECOVERED PLASMA SITES FOR  
Octapharma Pharmazeutika Produktions GmbH**

Dear Mrs. Wurstbauer,

We refer to the inspection performed for your company at Indiana Blood Center – 2021 South 3<sup>rd</sup> Street, Terre Haute 47802 IN on 19 – 22 September 2017 by the Austrian Agency for Health and Food Safety (AGES).

On the basis of the inspection performed on 19 – 22 September 2017, and subsequent correspondence, we can confirm that your operations relating to the safety and quality of plasma are in general compliance with the requirements of Commission Directives 2004/33/EC and 2005/62/EC implementing Directive 2002/98/EC of the European Parliament and of the Council, the relevant European Pharmacopoeia Monograph(s) and Directive 2003/94/EC.

This letter reflects the status of the plasma collection site at the time of the inspection noted above. The Issuing Authority has established appropriate inspection and control measures for the above named site to deem it compliant until September 2021. This letter should not be relied upon to reflect the compliance status if the above mentioned date has been exceeded, after which the issuing authority should be consulted.

The listing of this site in EMEA/H/PMF/000008/05 will be recommended.

Any matters arising from this inspection will be reviewed at the next inspection.


On behalf of the Austrian Federal Office for Safety in Health Care

*See official electronic signature at the end of the document*





Saadat Karmin  
am 8.10.2019

	<p>Dieses Dokument wurde amtssigniert. Informationen zur Prüfung der elektronischen Signatur und des Ausdrucks finden Sie unter <a href="http://www.basg.gv.at/amtssignatur">http://www.basg.gv.at/amtssignatur</a>.</p> <p>Bundesamt für Sicherheit im Gesundheitswesen Traisengasse 5, 1200 Wien</p>	
	Signaturwert	<pre>kAiuuIPAv0P2Bli1GmWuvBIDglaPbha e/fhtecmbupnerwhhbwSgbT1t1hPom s/IWg0fiaz2Iw/5Boll1BwzBstegTTd 0/b/tzplh/Sbal2PmlebsufPBI d2ofWocDGznTGlfAfvdBAPv2gupbkg nAff5p0smus/DBv1azAaA5emlp uvde2sTce5nz5/iAtcAkfevWIGfdv</pre>